Brigatinib (ALUNBRIG™): First Global Approval – resistance is futile in the battle against metastatic NSCLC

Brigatinib (ALUNBRIG™): First Global Approval –  resistance is futile in the battle against metastatic NSCLC

The recent first global approval of brigatinib has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight. Continue reading “Brigatinib (ALUNBRIG™): First Global Approval – resistance is futile in the battle against metastatic NSCLC”

Valbenazine (Ingrezza™): First Global Approval – taking back control for patients with Tardive Dyskinesia

Valbenazine (Ingrezza™): First Global Approval – taking back control for patients with Tardive Dyskinesia

The recent first global approval of valbenazine has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight. Continue reading “Valbenazine (Ingrezza™): First Global Approval – taking back control for patients with Tardive Dyskinesia”

Cerliponase Alfa (Brineura™): First Global Approval – first flicker of hope for families living with CLN2

Cerliponase Alfa (Brineura™): First Global Approval – first flicker of hope for families living with CLN2

The recent first global approval of cerliponase alfa has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight. Continue reading “Cerliponase Alfa (Brineura™): First Global Approval – first flicker of hope for families living with CLN2”

Ocrelizumab (Ocrevus™): First Global Approval – making a B-line to crushing the most aggressive form of MS

Ocrelizumab (Ocrevus™): First Global Approval – making a B-line to crushing the most aggressive form of MS

The recent first global approval of ocrelixumab has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight. Continue reading “Ocrelizumab (Ocrevus™): First Global Approval – making a B-line to crushing the most aggressive form of MS”

Dupilumab (Dupixent®): First Global Approval – don’t just scratch the surface – go skin deep and relieve the symptoms of uncontrolled eczema

Dupilumab (Dupixent®): First Global Approval – don’t just scratch the surface – go skin deep and relieve the symptoms of uncontrolled eczema

The recent first global approval of dupilumab has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight. Continue reading “Dupilumab (Dupixent®): First Global Approval – don’t just scratch the surface – go skin deep and relieve the symptoms of uncontrolled eczema”

Niraparib (Zejula™): First Global Approval – Oral maintenance therapy for recurrent ovarian-related cancer

Niraparib (Zejula™): First Global Approval –  Oral maintenance therapy for recurrent ovarian-related cancer

The recent first global approval of niraparib has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight.

Continue reading “Niraparib (Zejula™): First Global Approval – Oral maintenance therapy for recurrent ovarian-related cancer”